{
  "id": 5408554,
  "title": "Canada’s Drug Agency Issues Recommendation to Reimburse Yorvipath® (palopegteriparatide injection) With Conditions for Eligible Adults With Chronic Hypoparathyroidism",
  "url": "https://urgent.news/2026/09/03/canadas-drug-agency-issues-recommendation-to-reimburse-yorvipath",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-03T20:11:21.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/canadas-drug-agency-issues-recommendation-to-reimburse-yorvipath-palopegteriparatide-injection-with-conditions-for-eligible-adults-with-chronic-hypoparathyroidism"
  },
  "original_language": "en",
  "account": null,
  "summary": "Recommendation is an important step toward potential public reimbursement for eligible adults whose chronic hypoparathyroidism is not adequately controlled with conventional therapy MONTREAL, Sept. 03, 2026 (GLOBE NEWSWIRE) — Pendopharm, a division of Pharmascience Inc., in collaboration with Ascendis Pharma A/S, today announced that Canada’s Drug Agency, or CDA-AMC, has recommended that…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}